Olon, a company involved in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes, is expanding, and increasing production capacity, at its Mulazzano (Lodi, Italy) site.

The expansion strategy is supported by an annual investment plan that will reach 100 million euros in 2023.

“Olon was investing more than ever in these projects. We peaked with the level of investment in 2022, and in 2023 we expect to be above the peak of 2022,” said Paolo Tubertini, CEO Olon.

The investment will significantly increase production capacity of the finishing area at the Italian site in Mulazzano, with the installation of a new, advanced mill for grinding finished APIs.

The new equipment will also operate in full closed-loop containment, up to Level 4 OEB. The new technology, which is among the most advanced available on the market, improves efficiency at the grinding stage, increasing productivity and ensuring high API particle size standards.